Anestesia em criança com síndrome de Guillain-Barré após vacina de sarampo: relato de caso
Anesthesia in Guillain-Barré pediatric patient after measles vaccination: case report
Deoclécio Tonelli; Paula de Camargo Neves Sacco; Desire Calegari; Gustavo Cimerman; Carolina Mourão dos Santos; Rodrigo Gonzales Farath
Resumo
Palavras-chave
Abstract
Keywords
Referências
Sladky JT. Guillain-Barré syndrome in children. J Child Neurol. 2004;19:191-200.
Kuwabara S. Guillain-Barré syndrome: epidemiology, pathophysiology and management. Drugs. 2004;64:597-610.
Brooks H, Christian AS, May AE. Pregnancy, anaesthesia and Guillain-Barré syndrome. Anaesthesia. 2000;55:894-898.
Jones GD, Wilmshurst JM, Sykes K. Guillain-Barré syndrome: delayed diagnosis following anaesthesia. Paediatr Anaesth. 1999;9:539-542.
Paparounas K. Anti-GQ1b ganglioside antibody in peripheral nervous system disorders: pathophysiologic role and clinical relevance. Arch Neurol. 2004;61:1013-1016.
Nesbitt I. Pregnancy, anaesthesia and Guillain-Barré syndrome. Anaesthesia. 2000;55:1227-1228.
Morgan GE, Mikhail MS, Murray MJ. Neuromuscular Blocking Agents. Clin Anesthesiol. 2002:178-197.
Chan LY, Tsui MH, Leung TN. Guillain-Barré syndrome in pregnancy. Acta Obstet Gynecol Scand. 2004;83:319-325.
Zhou W, Pool V, Iskander JK. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS), United States 1991-2001. Surveill Summ. 2003;52:1-24.
Grose C, Spigland I. Guillain-Barré syndrome following administration of live measles vaccine. Am J Med. 1976;60:441-443.
Gatchalian S, Leboulleux D, Desauziers E. Immunogenicity and safety of a varicela vaccine, Okavax and a trivalent measles, mumps and rubella vaccine, MMR-II, administred concomitantly in health Filipino children aged 12-24 months. Southeast Asian J Trop Med Public Health. 2003;34:589-597.
Carabin H, Edmunds WJ, Kou U. The average cost of measles cases and adverse events following vaccination in industrialised countries. BMC Public Health. 2002;19:22.
Halsey NA. The science of evaluation of adverse events associated with vaccination. Semin Pediatr Infect Dis. 2002;13:205-214.
Davis RL, Marcuse E, Black S. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the vaccine safety datalink project. The vaccine safety datalink team. 1997;100:767-771.
Hesley TM, Reisinger KS, Sullivan BJ. Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity. Pediatr Infect Dis J. 2004;23:240-245.